---
schema_version: "secwatch.filing_event.v1"
accession: "0001581280-26-000044"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2026-08-03T11:21:11+00:00"
generated_at: "2026-08-03T11:25:11.467732+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience Q3 FY2026 revenue $118.4M (+23% YoY); raises FY guidance to $456-457M

## Summary
- Record revenue of $118.4M, up 23% YoY; 14th consecutive quarter of sequential growth.
- Gross margin 52.8%, up 120 bps sequentially; DSPS revenue $56.6M (+39% YoY), NGS $61.8M (+12% YoY).
- Net loss $35.1M ($0.56/share) vs net income $20.4M ($0.33) in prior year which included $48.8M gain from Atlas spin-out.
- Adjusted EBITDA -$11.3M; company reiterates Q4 FY2026 adjusted EBITDA breakeven target.
- FY2026 revenue guidance raised to $456-457M, up $12M at midpoint; cash $167M.

## SEC filing metadata
- accession: 0001581280-26-000044
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2026-08-03T11:21:11+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000158128026000044/0001581280-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000158128026000044/twist-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001581280-26-000044
- JSON: https://secwatch.observer/filing/0001581280-26-000044.json
- Plain text: https://secwatch.observer/filing/0001581280-26-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.